RxDoctor Payments Data

Rony Lee, MD

Family Medicine · Foley, ALNPI 1518944834

Payments from drug & device makers

$1,105in general payments, 2019–2025

Across 71 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$500
  • Galt Pharmaceuticals, LLC$116
  • Indivior Inc.$86
  • Amgen$57
  • Orexo US, Inc.$48
  • Zyla Life Sciences, Inc.$42
  • plus $257 from 12 others

What the payments were for

  • Food & beverage$1,105100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,105 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$71,273
Medicare patients
135
Services billed
649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl181$23,107
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen995$15,218
ZubsolvBuprenorphine Hcl/Naloxone Hcl11$8,085
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen227$4,219
Gabapentin663$3,559
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$3,379
Diclofenac Sodium93$2,729
Pregabalin124$1,687
AmantadineAmantadine Hcl73$1,003
Lubiprostone18$939
Baclofen176$777
Tramadol Hcl98$596
Ropinirole Hcl35$376
Tizanidine Hcl91$367
Cyclobenzaprine Hcl131$366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Orexo US, Inc.Zubsolv$48$8,08511 claims
Indivior Inc.Suboxone$86$3,37912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Foley

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →